PRNewswire12.02.19
CSA Medical Inc., has received CE Mark approval for its RejuvenAir System for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Bronchitis (CB). The RejuvenAir System is a cryosurgical device which applies Metered Cryospray ("MCS") of liquid nitrogen at -196˚C to targeted areas within the lungs through a minimally invasive bronchoscopic procedure. The extreme cold flash freezes damaged surface area lung cells which induces a rejuvenative healing process.
COPD with CB is a long-term, progressive lung disease that, over time, makes it hard to breathe. CB is characterized by a productive cough due to the overproduction of mucus and damaged cilia. According to the American Lung Association, CB affects more than 11 million Americans and is the third leading cause of disease-related deaths.
"While pharmaceutical options can decrease cough and mucus production, the RejuvenAir System offers the only treatment able to address the underlying cause of CB—while simultaneously treating the debilitating symptoms," said Heather Nigro, SVP of Regulatory, Quality and Clinical Affairs at CSA Medical. She continued, "This patient population now has an option that can dramatically improve their quality of life—that's exciting!"
The approval in the EU of this technology was supported by a prospective, multi-center, open-label, safety and efficacy study. The 35 patient study led to a significant improvement in patient-reported health-related quality of life, at least up to 12 months. Treatment with the RejuvenAir System was well tolerated and did not result in any significant or unexpected safety events.
"RejuvenAir Metered Cryospray can be safely delivered in patients with COPD and demonstrates clinical meaningful improvements in quality of life and patient-reported outcome scores out to 12 months," said professor Pallav Shah, M.D., F.R.C.P. from the Royal Brompton, London. "This is a promising new therapy for the millions of people who suffer from chronic bronchitis."
COPD with CB is a long-term, progressive lung disease that, over time, makes it hard to breathe. CB is characterized by a productive cough due to the overproduction of mucus and damaged cilia. According to the American Lung Association, CB affects more than 11 million Americans and is the third leading cause of disease-related deaths.
"While pharmaceutical options can decrease cough and mucus production, the RejuvenAir System offers the only treatment able to address the underlying cause of CB—while simultaneously treating the debilitating symptoms," said Heather Nigro, SVP of Regulatory, Quality and Clinical Affairs at CSA Medical. She continued, "This patient population now has an option that can dramatically improve their quality of life—that's exciting!"
The approval in the EU of this technology was supported by a prospective, multi-center, open-label, safety and efficacy study. The 35 patient study led to a significant improvement in patient-reported health-related quality of life, at least up to 12 months. Treatment with the RejuvenAir System was well tolerated and did not result in any significant or unexpected safety events.
"RejuvenAir Metered Cryospray can be safely delivered in patients with COPD and demonstrates clinical meaningful improvements in quality of life and patient-reported outcome scores out to 12 months," said professor Pallav Shah, M.D., F.R.C.P. from the Royal Brompton, London. "This is a promising new therapy for the millions of people who suffer from chronic bronchitis."
